This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.

First global participant joins the EVOKE trial

first global participant Alzheimers study version one

The team at the Memory Assessment and Research Centre (MARC), part of Southern Health NHS Foundation Trust, have recruited the first participant into a global study exploring the effect of a drug currently used to treat type 2 diabetes in patients with early Alzheimer's disease.

The EVOKE study, which is currently open at five UK sites, aims to recruit over 1,800 participants worldwide and will run for 173 weeks. Those interested in finding out more about the study can do so by searching 'EVOKE' on the bepartofresearch website. 

Dr Brady McFarlane, a Consultant Old Age Psychiatrist and the principal investigator for the study, said: “Thanks and well done to all the team at MARC for their hard work in setting up the study, but a special thank you to all of our trial volunteers for all of their efforts and commitment to dementia research.”

The EVOKE study is a randomised, double-blind, placebo-controlled clinical study looking at the effect and safety of oral semaglutide in patients with early Alzheimer's disease. The MARC research team welcome participant interest through the NIHR’s Be Part of Research website. To register your interest in dementia research, sign up to joindementiaresearch.